Riskpilot← Back to searchSign inGet full accessNATTOPHARMA AS
ASActiveOrg 987774339Etasje 05 Mustads Vei 1, 0283 OsloWholesale of other food · NACE 4638Est. 20055 employeeswww.nattopharma.com
Revenue 2024
NOK 29,6M
-85% vs 2023
EBITDA margin
85.4%
-80% vs 2023
Equity ratio
55.3%
Financial strength
Net profit 2024
NOK 35,6M
-68% vs 2023
| Revenue | NOK 29,6M | -85% |
| EBITDA | NOK 25,3M | -80% |
| Net profit | NOK 35,6M | -68% |
| Total assets | NOK 47,6M | -80% |
| Equity | NOK 26,3M | -61% |
| Employees | 5 | — |
Legal name
NATTOPHARMA AS
Org number
987774339
Legal form
Aksjeselskap
NACE code
4638 · Wholesale of other food
Founded
27. januar 2005
Share capital
NOK 1 050 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene eller to styremedlemmer i fellesskap.
Company purpose
Direkte og via eierinteresser i andre selskaper å utvikle, distribuere og selge ernæringsprodukter og pharmasiprodukter, samt tilknyttede tjenester til dette.
Address
Etasje 05 Mustads Vei 1, 0283 Oslo
Website
www.nattopharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18 986 | 24 374 | 26 494 | 34 217 | 50 550 | 70 054 | 69 247 | 89 543 | 95 925 | 71 314 | 196 104 | 29 582 |
| Staff expenses | −11 263 | −4 097 | −6 645 | −6 021 | −10 200 | −15 339 | −15 232 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −21 477 | −12 304 | −22 409 | −12 892 | −5 430 | −3 804 | −344 | 897 | −24 233 | −6 612 | 127 167 | 25 251 |
| Depreciation & amort. | −1 130 | −438 | −399 | −373 | −620 | −625 | −1 427 | −1 369 | −4 377 | −0 | −10 786 | −345 |
| EBIT | −22 607 | −12 742 | −22 808 | −13 265 | −6 050 | −4 429 | −1 771 | −472 | −28 610 | −6 612 | 116 381 | 24 906 |
| Net financials | −2 025 | 2 478 | 5 805 | −2 024 | 2 057 | 3 755 | −31 327 | 24 435 | 2 001 | 108 144 | 12 978 | 10 696 |
| Profit before tax | −24 632 | −10 264 | −17 003 | −15 289 | −3 993 | −674 | −33 098 | 23 963 | −26 609 | 101 532 | 129 359 | 35 602 |
| Tax | 3 906 | −0 | −0 | −0 | −0 | −0 | −0 | −28 820 | 17 820 | −8 000 | 19 000 | −0 |
| Net profit | −28 538 | −10 264 | −17 003 | −15 289 | −3 993 | −674 | −33 098 | 52 783 | −44 429 | 109 532 | 110 359 | 35 602 |
| Item | 2008 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 15 777 | 90 507 | 130 590 | 114 898 | 177 813 | 173 582 | 163 238 | 233 356 | 237 389 | 285 609 | 234 034 | 47 555 |
| Equity | −5 613 | 85 112 | 115 138 | 102 905 | 165 797 | 161 385 | 134 128 | 201 669 | 170 151 | 92 392 | 67 751 | 26 292 |
| Long-term debt | 0 | 29 | 0 | 0 | 0 | 0 | 800 | 0 | 26 764 | 2 932 | 11 858 | 0 |
| Short-term debt | 21 390 | 5 366 | 15 452 | 11 993 | 12 016 | 12 197 | 28 309 | 31 687 | 40 474 | 190 285 | 154 426 | 21 264 |
| Total debt | 21 390 | 5 395 | 15 452 | 11 993 | 12 016 | 12 197 | 29 109 | 31 687 | 67 238 | 193 217 | 166 284 | 21 264 |
EBITDA margin
85.4%
This company
15.8%
Market median
+441% vs market
20082024
Equity ratio
55.3%
This company
38.2%
Market median
+45% vs market
20082024
Return on equity
135.4%
This company
18.4%
Market median
+636% vs market
20082024
Net profit margin
120.3%
This company
8.1%
Market median
+1385% vs market
20082024
Asset turnover
0.62×
This company
1.12×
Market median
-45% vs market
20082024
Debt / equity
0.81×
This company
0.62×
Market median
+31% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KØ Deputy Member | Deputy Member | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Immunopharma As | Company | 100.0% | 100.0% | 2024 |
Compagnie Des Levures Lesaffre | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NATTOPHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kim Øien | Deputy Member | 0 companies |
| Katarzyna Zdzislawa Maresz | Board of Directors | 0 companies |
| Ingrid Anette Elmqvist | Board of Directors | 0 companies |
| Sjur Thorsheim | Board of Directors | 0 companies |
| Jerome Jacques Robert Ronze | Chairman | 0 companies |
| Stefan Halden | Board of Directors | 0 companies |
| Frederique Annie Francoise Clusel | Board of Directors | 0 companies |
| Marc Georges Claude Philouze | Chairman | 0 companies |
| Giuseppe Ettore Autieri | Board of Directors | 0 companies |
| Frode Marc Bohan | Chairman | 0 companies |
| Knut Christian Espeseth | Chairman | 0 companies |
| Raffaella Mangiagalli | Board of Directors | 0 companies |
| Kjetil Ramsøy | Board of Directors | 0 companies |